Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Drops By 6.3%

HilleVax, Inc. (NASDAQ:HLVX) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,180,000 shares, a decrease of 6.3% from the October 15th total of 1,260,000 shares. Based on an average daily volume of 259,400 shares, the days-to-cover ratio is presently 4.5 days. Approximately 6.4% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a report on Monday, August 12th. Six investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.00.

HilleVax Trading Down 0.5 %

Shares of NASDAQ HLVX opened at $1.82 on Wednesday. HilleVax has a twelve month low of $1.55 and a twelve month high of $20.22. The stock has a 50 day moving average of $1.83 and a two-hundred day moving average of $5.60. The stock has a market cap of $90.65 million, a P/E ratio of -0.59 and a beta of 0.78.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). As a group, research analysts predict that HilleVax will post -2.64 earnings per share for the current year.

Institutional Investors Weigh In On HilleVax

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new stake in HilleVax in the first quarter valued at approximately $80,000. Tidal Investments LLC purchased a new stake in shares of HilleVax during the first quarter worth approximately $207,000. Maven Securities LTD purchased a new stake in shares of HilleVax during the second quarter worth approximately $217,000. BML Capital Management LLC purchased a new stake in shares of HilleVax during the third quarter worth approximately $35,000. Finally, Algert Global LLC purchased a new stake in shares of HilleVax during the second quarter worth approximately $519,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.